Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Surg Oncol. 2021 May;123(6):1414-1422. doi: 10.1002/jso.26394.
Systemic chemotherapy improves the survival of patients who undergo pancreatectomy, but whether chemotherapy should be delivered before or after surgery remains debated. At The University of Texas MD Anderson Cancer Center, localized pancreatic ductal adenocarcinoma (PDAC) has been preferentially treated with preoperative therapy-a practice supported by a robust history of institutional and national trials. In the following review, we discuss the historical use of perioperative therapy, our experience with it at MD Anderson Cancer Center and internationally, and the future of treatment and trials for PDAC.
系统化疗可改善接受胰腺切除术患者的生存，但化疗应在手术前还是手术后进行仍存在争议。在德克萨斯大学 MD 安德森癌症中心，局部胰腺导管腺癌 (PDAC) 优先采用术前治疗——这种做法得到了大量机构和国家试验的支持。在以下综述中，我们讨论了围手术期治疗的历史应用、我们在 MD 安德森癌症中心和国际上的经验，以及 PDAC 的治疗和试验的未来。
